Roquefort Therapeutics plc (LON:ROQ – Get Free Report)’s share price fell 7.1% during trading on Friday . The stock traded as low as GBX 5 ($0.06) and last traded at GBX 5.20 ($0.07). 2,808,162 shares were traded during trading, an increase of 639% from the average session volume of 379,845 shares. The stock had previously closed at GBX 5.60 ($0.07).
Roquefort Therapeutics Stock Performance
The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The company has a market cap of £6.62 million, a price-to-earnings ratio of -512.80 and a beta of 0.05. The stock has a 50 day moving average price of GBX 3.78 and a two-hundred day moving average price of GBX 4.25.
About Roquefort Therapeutics
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.
See Also
- Five stocks we like better than Roquefort Therapeutics
- What is Short Interest? How to Use It
- Battle of the Retailers: Who Comes Out on Top?
- What is a support level?
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- The How And Why of Investing in Oil Stocks
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.